Taysha Gene Therapies | DEFA14A: Others
Taysha Gene Therapies | ARS: Annual Report to Security Holders
Taysha Gene Therapies | DEF 14A: Definitive information statements
Taysha Gene Therapies | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Taysha Gene Therapies | 8-K: Current report
Taysha Gene Therapies | 10-K: Annual report
Taysha Gene Therapies | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Venrock Healthcare Capital Partners III, L.P.(5.6%),VHCP Co-Investment Holdings III, LLC(5.6%), etc.
Taysha Gene Therapies | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-RA Capital Management, L.P.(9.99%),Peter Kolchinsky(9.99%), etc.
Taysha Gene Therapies | SC 13G: Statement of acquisition of beneficial ownership by individuals-RTW Investments, LP(9.8%),Roderick Wong, M.D.(9.8%)
Taysha Gene Therapies | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-TCG Crossover GP I, LLC(1.6%),TCG Crossover Fund I, L.P.(1.6%), etc.
Taysha Gene Therapies | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-FMR LLC(12.002%),Abigail P. Johnson(12.002%)
Taysha Gene Therapies | 4: Statement of changes in beneficial ownership of securities-Officer Alam Kamran
Taysha Gene Therapies | 8-K: Current report
Taysha Gene Therapies | 4: Statement of changes in beneficial ownership of securities-Officer Alam Kamran
Taysha Gene Therapies | 4: Statement of changes in beneficial ownership of securities-Officer Nagendran Sukumar
Taysha Gene Therapies | 4: Statement of changes in beneficial ownership of securities-Officer Nolan Sean P.
Taysha Gene Therapies | 8-K: Current report
Taysha Gene Therapies | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Taysha Gene Therapies | 4: Statement of changes in beneficial ownership of securities-Chief Financial Officer Alam Kamran
Taysha Gene Therapies | 4: Statement of changes in beneficial ownership of securities-Officer Nagendran Sukumar
No Data